Detalhe da pesquisa
1.
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
Cancer
; 124(12): 2561-2569, 2018 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29723393
2.
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Am J Hematol
; 90(6): 487-92, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25691474
3.
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Br J Haematol
; 166(1): 77-83, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24661044